Dr Stefan Symeonides, a Senior Clinical Lecturer at the University of Edinburgh, will provide expert advice as Medannex prepares for Phase I clinical trials.
Dr Symeonides is a Phase I trial specialist with a focus on immunotherapy and leads the Edinburgh Cancer Centre Phase I trials unit. His collaboration with Medannex has been facilitated by Edinburgh Innovations.
Medannex’s therapeutic approach, using novel antibodies to specifically modulate the innate and adaptive immune systems, could prove significant for the treatment of cancers and autoimmune diseases, and has received independent validation via grant awards from both Scottish Enterprise and Innovate UK.
Ian Abercrombie, Chief Executive Officer at Medannex, said: “We are thrilled to welcome Dr Symeonides as an advisor to Medannex at this important time. His expertise in both immunology and Phase I studies will be invaluable as we prepare to take our lead molecule in to the clinical phase of its development.”
Dr Symeonides said: “Medannex has identified a novel and promising target for immunotherapy, and I am delighted to offer guidance as the company prepares for its First-in-Human study.”